RNF43 mutation

Predictive impact of RNF43 mutation in pMMR/MSS BRAFV600E #mCRC treated with target therapy or CTx at #WCGIC2023 👉🎯💊 is effective in all pts, but more effective in mRNF cases 👉We need predictive biomarker -> prospective validation warranted @WCGIC @myESMO @OncoAlert (@ArndtVogel)

The mouse model of RNF43 mutant #PancreaticCancer we have developed demonstrates a completely distinct immune milieu & #immunotherapy response than RNF43 wild type cancer (mechanism below): https://t.co/EKteaQuCUH Now we need to run the clinical trial! (@Aiims1742)

Most fascinated by data that absence of recurrence post resection in #PancreaticCancer correlated with RNF43 mutations. 2nd paper to show this after @nigeljamieson @dkfchang study in @AGA_Gastro. Rnf43 mutations create a favorable milieu impacting outcomes https://t.co/2wi6nflBRW (@Aiims1742)

RNF43 mutations facilitate mucinous colorectal cancer metastasis via formation of a tumour-intrinsic niche | bioRxiv https://t.co/PkyZWOejAv (@weldeiry)

New #ColorectalCancer research from #AACRcrc22 shows an oncogenic role and therapeutic options for one of the most frequent colorectal cancer mutations: RNF43 G659fs. Research presented by Dana-Farber's Marios Giannakis, MD, PhD (@GiannakisLab) (@DanaFarberNews)

🧑🏼‍🔬​ Investigadores del @VHIO descubren que pacientes con cáncer colorrectal metastásico con microsatélites estables con mutación BRAFV600E y mutaciones RNF43 serán los que tengan mejor respuesta @vallhebron @NCBI @TaberneroJosep @elena_elez https://t.co/15C2SW5ZmZ (@isanidad)

🧑🏼‍🔬 ​Las mutaciones en el gen RNF43 en #pacientes con cáncer colorrectal metastásico con microsatélites estables, son un biomarcador para identificar los que mejor responderán a la doble terapia @VHIO @vallhebron @NCBI @TaberneroJosep @elena_elez https://t.co/15C2SW5ZmZ (@isanidad)

RNF43 mutation as a biomarker for efficacy on Beacon doublet for #BRAFV600E mutated #CRC patients? Very interesting paper 👇👇 @elena_elez #CRCSM (@manjuggm)

Understanding the most frequent RNF43 gene mutation in #ColorectalCancer: @NatureComms paper by @GiannakisLab finds this poorly understood mutation acts as driver, helping cancer grow, but the good news is they've also id'd cancer drugs that target it ▶️ https://t.co/vrvLkMar6V (@DanaFarberNews)

Our latest research showing an oncogenic role and therapeutic options for one of the most frequent Colorectal Cancer mutations (RNF43 G659fs) is now published @NatureComms https://t.co/yzul41hRBU (@GiannakisLab)

In @jclinicalinvest A p300/GATA6 axis determines differentiation and Wnt dependency in #PancreaticCancer models https://t.co/7ISifBQcKO What renders certain RNF43 mutant cancers resistant to Wnt ligand inhibitors? This study suggests loss of EP300/GATA6 induced differentiation. (@Aiims1742)

New in @CCR_AACR: Comprehensive analysis of R-spondin fusions and RNF43 mutations implicate novel therapeutic options in #colorectalcancer. Dr. Andreas Seeber et al. @carisls GI Precision Oncology Alliance collaboration. https://t.co/a62nHhBIMD #ColorectalCancerAwarenessMonth (@cancerassassin1)

As a corollary, a KRAS + RNF43 + TP53 mutant colloid carcinoma (#PancreaticCancer / #PancreaticDuctalAdenocarcinoma) arising in an #IPMN. #PancreaticCysts #EarlyDetection (@PancPathologist)

Molecular Analyses of Left- & Right-Sided Tumors in Adolescents & YAs w/ #CRCSM "RT showed higher mutation rates compared w/ LT in several genes including BRAF (10.3% vs. 2.8%), KRAS (64.1% vs. 45.5%), PIK3CA (27% vs. 11.2%), & RNF43 (24.2% vs. 2.9%)" https://t.co/6pcgU9gB8N (@fireflyann)

Proposed model of how Rnf43 mutations alter the #PancreaticCancer TME to a relatively favorable milieu via HDAC mediated suppression of chemokine ligand CXCL5. Can this be exploited in the clinic? Second manuscript in works with more insights on unexpected Rnf43 role in cancer. (@Aiims1742)

The surprise - single cell RNA sequencing of early, intermediate & moribund KRC pancreas, showing the evolution of a tumor microenvironment that is entirely distinct from the usual KRAS;p53 (KPC) TME. TL;DR: The TME of Rnf43 mutant tumors might be poised for #immumotherapy. (@Aiims1742)

Rnf43 is mutated in ~8% of #PancreaticCancer & a larger proportion of cystic precursor lesions (see prior work by @lauradelongwood). Rnf43 mutations are thought to result in aberrant Wnt activation. But Phase 1 of porcupine inhibitor in Rnf43 mut cancers had almost no responses. (@Aiims1742)